retatrutide 2025 Back in 2023 we saw truly unprecedented data for a new drug called ' Retatrutide', which binds to — and activates — 3 receptors: the GLP1 receptor (like Semaglutide), the GIP receptor (like Retatrutide (Eli Lilly's triple GLP-1/GIP/Glucagon

Theres research supporting its effectiveness in reducing digestive discomfort

For example, GLP-1R expression in the cardiovascular and central nervous systems is thought to, at least in part, mitigate risk of myocardial infarction, stroke, and neurodegenerative impairments

Being aware of these side effects is essential for ensuring medication adherence and offering emotional support and reassurance to patients as they adapt to their weight loss journey

Before injecting, always follow these preparatory steps: Check the expiry date on the device and confirm you have the correct medicine, dose, and scheduled time

Deganutti G, Liang Y-L, Zhang X et al (2022) Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation

Graphic by Clara Turnage/University Marketing and Communications For patients whose insurance wont cover GLP-1 medications, lower-cost compounded versions can seem like an attractive alternative, but the researchers urge caution